Safety of tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib

被引：0

作者：

Liam, C. K. ^{[1
]}

Kim, T. M. ^{[2
,3
]}

Yang, J-J. ^{[4
,5
]}

Huang, C. ^{[6
]}

Voon, P-J. ^{[7
]}

Tho, L. M. ^{[8
]}

Zhou, Q. ^{[9
]}

Wang, J. ^{[10
]}

Hayashi, H. ^{[11
]}

Tan, D. S. W. ^{[12
]}

Danchaivijitr, P. ^{[13
]}

Nguyen, V. N. ^{[14
]}

Wong, K. H. ^{[15
]}

Yang, J. C-H. ^{[16
]}

Le, X. ^{[17
]}

Ellers-Lenz, B. ^{[18
]}

Karachaliou, N. ^{[19
]}

Ghori, V. ^{[20
]}

Berghoff, K. ^{[20
]}

Wu, Y-L. ^{[5
,21
]}

机构：

[1] Univ Malaya, Dept Med, Fac Med, Kuala Lumpur, Malaysia

[2] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea

[3] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[4] Guangdong General Hosp, Guangdong Lung Canc Inst, Dept Oncol, Guangzhou, Peoples R China

[5] Guangdong Acad Med Sci, Guangzhou, Peoples R China

[6] Fujian Canc Hosp, Dept Thorac Oncol, Fujian, Peoples R China

[7] Hosp Umum Sarawak, Sarawak, Malaysia

[8] Pantai Hosp Kuala Lumpur, Dept Oncol, Kuala Lumpur, Malaysia

[9] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu, Sichuan, Peoples R China

[10] Fudan Univ, Shanghai Canc Ctr, Dept Oncol, Shanghai, Peoples R China

[11] Kindai Univ, Dept Med Oncol, Fac Med, Osaka, Japan

[12] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore

[13] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Internal Med,Div Med Oncol, Bangkok, Thailand

[14] Natl Lung Hosp, Hanoi, Vietnam

[15] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Peoples R China

[16] Natl Taiwan Univ, Canc Ctr, Dept Med Oncol, Taipei, Taiwan

[17] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

[18] Merck Healthcare KGaA, Dept Biostat, Darmstadt, Germany

[19] Merck Healthcare KGaA, Global Clin Dev, Darmstadt, Germany

[20] Merck Healthcare KGaA, Global Patient Safety, Darmstadt, Germany

[21] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.644

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

566P

引用

页码：S1691 / S1691

页数：1

共 50 条

[21] Savolitinib Plus Osimertinib in EGFR-Mutant NSCLC with MET Overexpression and Acquired Resistance to Previous EGFR Inhibitor
Mao, Y.
Huang, Z.
Cai, D.
Lou, R.
Shen, C.
Wang, X.
Liu, Y.
Qi, X.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S638 - S638
[22] Safety and efficacy of osimertinib plus bevacizumab as first-line treatment in EGFR-mutant NSCLC with brain metastases: A dynamic ctDNA-guided study
Wei, Fang
An, Juan
Hua, Yichun
Ding, Xiaosheng
Sun, Shibin
Li, Xiaoyan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[23] INSIGHT2: Tepotinib plus osimertinib in pts with EGFR-mutant NSCLC and acquired resistance to 1L osimertinib due to METamp
Morise, Masahiro
Sakai, Hiroshi
Kato, Terufumi
Tokito, Takaaki
Takeda, Masayuki
Tanaka, Hiroshi
Chikamori, Kenichi
Daga, Haruko
Kijima, Takashi
Ohashi, Kadoaki
Karachaliou, Niki
Ellers-Lenz, Barbara
Wu, Yi-Long
ANNALS OF ONCOLOGY, 2021, 32 : S309 - S309
[24] Assessment of early resistance mechanisms to first-line osimertinib in EGFR-mutant NSCLC using spatial transcriptomics
de Garibay, G. Ruiz
Roch, B.
Garrido Lopez, P.
Isla, D.
Aguado, C.
Callejo Perez, A.
Marse Fabregat, R.
Garcia Campelo, M. R.
Blasco Cordellat, A.
Sanchez Torres, J. M.
Bernabe Caro, R.
Juan Vidal, O. J.
Carpeno, J. De Castro
Franco, F. F.
Ramos Garcia, I.
Gomez Rueda, A.
Conde Gallego, E.
Ponce Aix, S.
Paz-Ares, L.
Zugazagoitia, J.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1015 - S1016
[25] Tepotinib plus gefitinib in patients with EGFR-mutant NSCLC with MET amplification: Final analysis of INSIGHT
Itchins, Malinda
Liam, Chong Kin
Ahmad, Azura
Hsia, Te-Chun
Zhou, Janying
Kim, Dong-Wan
Soo, Ross Andrew
Cheng, Ying
Lu, Shun
Shin, Sang Won
Yang, James Chih-Hsin
Zhang, Yiping
Zhao, Jun
Bruns, Rolf
Johne, Andreas
Wu, Yi-Long
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 82 - 83
[26] Tepotinib plus gefitinib in patients with EGFR-mutant NSCLC with MET amplification: Final analysis of INSIGHT
Liam, Chong Kin
Ahmad, Azura Rozila
Hsia, Te-Chun
Zhou, Jianying
Kim, Dong-Wan
Soo, Ross Andrew
Cheng, Ying
Lu, Shun
Shin, Sang Won
Yang, James Chih-Hsin
Zhang, Yiping
Zhao, Jun
Bruns, Rolf
Johne, Andreas
Wu, Yi-Long
CANCER RESEARCH, 2022, 82 (12)
[27] Safety of tepotinib plus EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC
Nadal, E.
Kim, T. M.
Guarneri, V.
Voon, P. J.
Lim, B. K.
Wislez, M.
Huang, C.
Liam, C. K.
Mazieres, J.
Tho, L. M.
Hayashi, H.
Nguyen, N.
Chia, P. L.
De Marinis, F.
Brutlach, S.
Adrian, S.
Ellers-Lenz, B.
Berghoff, K.
Karachaliou, N.
Wu, Y-L.
ANNALS OF ONCOLOGY, 2023, 34
[28] Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With METamp After Osimertinib First-Line Treatment
Corassa, Marcelo
Abreu, Rodrigo Fonseca
Cordeiro de Lima, Vladmir Claudio
Torrezan, Giovana Tardim
Cavalher, Felicia Peterson
Silva, Tullio Novaes
de Oliveira, Thiago Bueno
Freitas, Helano Carioca
Carraro, Dirce Maria
Costa, Felipe D'Almeida
JCO PRECISION ONCOLOGY, 2022, 6
[29] First-Line Osimertinib in Asian Patients with Advanced EGFR-Mutant Lung Cancer
Tan, W.
Chua, B.
Yin, D.
Tan, S. H.
Tan, D.
Ang, M.
Kanesvaran, R.
Jain, A.
Rajasekaran, T.
Lai, G.
Toh, C. K.
Tan, E.
Ng, Q. S.
Lim, W.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S607 - S607
[30] INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study
Yang, J. C-H.
Ellers-Lenz, B.
Straub, J.
Johne, A.
Wu, Y-L.
ANNALS OF ONCOLOGY, 2019, 30

← 1 2 3 4 5 →